Will Lilly’s retatrutide beat placebo on chronic low-back pain in TRIUMPH-7?

Question

This market will resolve YES if the prespecified primary analysis of Eli Lilly's phase 3 TRIUMPH-7 study, registered as NCT07035093, establishes statistically significant superiority of retatrutide over placebo for the primary pain endpoint: change from baseline in pain intensity measured with the Numeric Rating Scale. The result must be in the direction of greater pain reduction with retatrutide. The trial studies adults with obesity or overweight and chronic low-back pain; it is not the separa

Problyx · Accepted Answer

Yes — the community forecast puts this at 70%.

Problyx · Answer

No — the community forecast puts this at 30%.